Skip to main content

Table 1 Clinical studies on selenium and radiotherapy between 1987 and 2012

From: Updates on clinical studies of selenium supplementation in radiotherapy

Study no.

Reference

Site of research

Number of patients

Study design

Type of cancer/disease

Radiotherapy delivery method

1

Pothier et al. [17]

USA

n = 71

Observation of Se levels

Upper gastrointestinal cancer

Not mentioned

2

Antila et al. [18]

Finland

n = 24

Observation of Se levels

Breast cancer

Energy photons followed by 6–12 MeV electrons

3

Piccinini et al. [19]

Italy

n = 66

Observation of Se levels

Breast cancer (n = 38), lung cancer (n = 28)

Not mentioned

4

Rostkowska-Nadolska et al. [20]

Poland

n = 78

Observation of Se levels

carcinoma of the larynx

X-Ray therapy

5

Yadav et al. [21]

India

n = 30

Observation of Se levels

Head and neck cancer

Not mentioned

6

Last et al. [22]

UK

n = 100

Observation of Se levels

Non-Hodgkin’s lymphoma

Not mentioned

7

Fraunholz et al. [23]

Germany

n = 224

Observation of Se levels

Breast cancer (n = 94); cervical csncer (n = 25); head and neck cancer (n = 23); lung cancer (n = 19); prostate (n = 13); other (n = 50)

6-MV and/or 25-MV photons generated by a linear accelerator

8

Franca et al. [24]

Brazil

n = 209

Observation of Se levels

Breast cancer

Not mentioned

9

Zeng YC et al. [25]

China

n = 95

Observation of Se levels

Non-small cell lung cancer with brain metastases

6MV external beam radiotherapy

10

Eroglu C et al. [26]

Turkey

n = 47

Observation of Se levels

Head and neck cancer

Not mentioned

11

Pakdaman, [27]

Germany

n = 32

Se supplementation

Brain tumor

Not mentioned

12

Kiremidjian-Schumacher et al. [28]

USA

n = 33 supplemented (n = 17) placebo (n = 16)

Se supplementation

Head and neck cancer

Not mentioned

13

Micke et al. [29]

Germany

n = 48

Se supplementation

Secondary lymphedema

a linear accelerator with 6-MeV photons or a 60Co treatment unit

14

Elango et al. [30]

India

n = 126

Se supplementation

Oral cancer

a tele-cobalt beam (Theratron-780-60Co; phoenix-60Co; Gammatron-60Co)

15

Muecke et al. [31]

Germany

n = 81 supplemented (n = 39) control group (n = 42)

Se supplementation

Cervical cancer (n = 11); uterine cancer (n = 70)

6- to 18-MV linear accelerator

16

Buntzel et al. [32]

Germany

n = 39

Se supplementation

Head and neck cancer

Not mentioned

   

Total = 1303

  Â